The University of Chicago Header Logo

Connection

George Perry to Alzheimer Disease

Back to Details
This is a "connection" page, showing publications George Perry has written about Alzheimer Disease.
George Perry
Connection Strength
10.676
Alzheimer Disease
  1. Central role of brain regulatory T cells in the inflammatory cascade in Alzheimer's disease. Proc Natl Acad Sci U S A. 2024 Aug 06; 121(32):e2412255121.
    View in: PubMed
    Score: 0.681
  2. Lessons from antiamyloid-ß immunotherapies in Alzheimer's disease. Handb Clin Neurol. 2023; 193:267-292.
    View in: PubMed
    Score: 0.611
  3. Neuropathologic Changes Provide Insights into Key Mechanisms of Alzheimer Disease and Related Dementia. Am J Pathol. 2022 10; 192(10):1340-1346.
    View in: PubMed
    Score: 0.593
  4. Status and future directions of clinical trials in Alzheimer's disease. Int Rev Neurobiol. 2020; 154:3-50.
    View in: PubMed
    Score: 0.515
  5. Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. Antioxid Redox Signal. 2021 03 10; 34(8):591-610.
    View in: PubMed
    Score: 0.515
  6. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics. 2019 07; 16(3):666-674.
    View in: PubMed
    Score: 0.479
  7. The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Lab Invest. 2019 07; 99(7):958-970.
    View in: PubMed
    Score: 0.467
  8. Iron·ic facts about dementia. J Neurol Neurosurg Psychiatry. 2018 05; 89(5):446-447.
    View in: PubMed
    Score: 0.433
  9. Thermodynamics of Amyloid-ß Fibril Elongation: Atomistic Details of the Transition State. ACS Chem Neurosci. 2018 04 18; 9(4):783-789.
    View in: PubMed
    Score: 0.431
  10. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer's disease. Sci Rep. 2016 04 28; 6:24873.
    View in: PubMed
    Score: 0.384
  11. The complexities of the pathology-pathogenesis relationship in Alzheimer disease. Biochem Pharmacol. 2014 Apr 15; 88(4):671-6.
    View in: PubMed
    Score: 0.328
  12. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease. Antioxid Redox Signal. 2013 Jun 20; 18(18):2444-57.
    View in: PubMed
    Score: 0.304
  13. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res. 2012 Nov; 43(8):694-8.
    View in: PubMed
    Score: 0.301
  14. Mark A. Smith: neurocytochemistry innovator. J Neurochem. 2012 Mar; 120(6):1139-40.
    View in: PubMed
    Score: 0.286
  15. Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radic Biol Med. 2012 Feb 01; 52(3):699-704.
    View in: PubMed
    Score: 0.282
  16. Mark A. Smith: the scientist, the man. Int J Exp Pathol. 2011 Oct; 92(5):297-8.
    View in: PubMed
    Score: 0.280
  17. Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother. 2010 Jul; 10(7):1201-8.
    View in: PubMed
    Score: 0.257
  18. Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches. Int J Mol Sci. 2009 Mar; 10(3):1386-1406.
    View in: PubMed
    Score: 0.235
  19. RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathol. 2009 Jul; 118(1):151-66.
    View in: PubMed
    Score: 0.234
  20. Label-Free In Situ Chemical Characterization of Amyloid Plaques in Human Brain Tissues. ACS Chem Neurosci. 2024 04 03; 15(7):1469-1483.
    View in: PubMed
    Score: 0.166
  21. Prion disease and Alzheimer's disease: pathogenic overlap. Acta Neurobiol Exp (Wars). 2004; 64(1):11-7.
    View in: PubMed
    Score: 0.164
  22. Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on a-Synuclein and Tau Aggregation. ACS Chem Neurosci. 2023 11 01; 14(21):3913-3927.
    View in: PubMed
    Score: 0.161
  23. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol. 2003 Dec; 106(6):552-6.
    View in: PubMed
    Score: 0.160
  24. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol. 2003 May; 162(5):1623-7.
    View in: PubMed
    Score: 0.156
  25. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals. 2003 Mar; 16(1):77-81.
    View in: PubMed
    Score: 0.154
  26. No Evidence of Increased Chronic Traumatic Encephalopathy Pathology or Neurodegenerative Proteinopathy in Former Military Service Members: A Preliminary Study. J Alzheimers Dis. 2019; 67(4):1277-1289.
    View in: PubMed
    Score: 0.116
  27. Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer's disease subjects. Nanoscale. 2018 Jul 05; 10(25):11782-11796.
    View in: PubMed
    Score: 0.112
  28. Cerebrovascular and mitochondrial abnormalities in Alzheimer's disease: a brief overview. J Neural Transm (Vienna). 2016 Feb; 123(2):107-11.
    View in: PubMed
    Score: 0.088
  29. Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer's disease. J Health Care Poor Underserved. 2013 Nov; 24(4 Suppl):70-8.
    View in: PubMed
    Score: 0.081
  30. Antimicrobial peptide ß-defensin-1 expression is upregulated in Alzheimer's brain. J Neuroinflammation. 2013 Oct 18; 10:127.
    View in: PubMed
    Score: 0.081
  31. Is exercise-in-a-bottle likely to proffer new insights into Alzheimer's disease? J Neurochem. 2013 Oct; 127(1):4-6.
    View in: PubMed
    Score: 0.080
  32. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors. 2012 Mar-Apr; 38(2):133-8.
    View in: PubMed
    Score: 0.072
  33. Mark A. Smith, 1965-2010: consummate student of pathogenesis. Int J Clin Exp Pathol. 2011; 4(7):731-2.
    View in: PubMed
    Score: 0.070
  34. A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules. Lab Invest. 2011 Dec; 91(12):1777-86.
    View in: PubMed
    Score: 0.070
  35. Widespread distribution of reticulon-3 in various neurodegenerative diseases. Neuropathology. 2010 Dec; 30(6):574-9.
    View in: PubMed
    Score: 0.066
  36. Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother. 2010 May; 10(5):683-91.
    View in: PubMed
    Score: 0.063
  37. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep. 2010; 15(4):161-8.
    View in: PubMed
    Score: 0.062
  38. Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging (Albany NY). 2009 Apr; 1(4):382-8.
    View in: PubMed
    Score: 0.059
  39. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis. 2009; 18(2):447-52.
    View in: PubMed
    Score: 0.058
  40. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int. 2009 Feb; 54(2):84-8.
    View in: PubMed
    Score: 0.058
  41. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008 Jun; 67(6):523-31.
    View in: PubMed
    Score: 0.056
  42. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem. 2008 Aug; 106(3):1350-6.
    View in: PubMed
    Score: 0.055
  43. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother. 2008 Apr-May; 62(4):199-207.
    View in: PubMed
    Score: 0.055
  44. The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotox Res. 2007 Dec; 12(4):269-74.
    View in: PubMed
    Score: 0.054
  45. Iron: the Redox-active center of oxidative stress in Alzheimer disease. Neurochem Res. 2007 Oct; 32(10):1640-5.
    View in: PubMed
    Score: 0.052
  46. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother. 2007 May; 7(5):473-85.
    View in: PubMed
    Score: 0.052
  47. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007 Jun; 321(3):823-9.
    View in: PubMed
    Score: 0.051
  48. Increased expression of p130 in Alzheimer disease. Neurochem Res. 2007 Apr-May; 32(4-5):639-44.
    View in: PubMed
    Score: 0.049
  49. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006 Jul; 65(7):631-41.
    View in: PubMed
    Score: 0.049
  50. Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. Sci Aging Knowledge Environ. 2006 May 03; 2006(8):pe10.
    View in: PubMed
    Score: 0.048
  51. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol. 2006 Jun; 111(6):503-9.
    View in: PubMed
    Score: 0.048
  52. Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen. 2006 Mar-Apr; 21(2):126-30.
    View in: PubMed
    Score: 0.048
  53. Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res. 2005 Oct; 2(4):419-23.
    View in: PubMed
    Score: 0.046
  54. Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective? Int J Exp Pathol. 2005 Jun; 86(3):133-8.
    View in: PubMed
    Score: 0.045
  55. Oxidative stress and neurodegeneration. Ann N Y Acad Sci. 2005 Jun; 1043:545-52.
    View in: PubMed
    Score: 0.045
  56. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev. 2004 Jul; 3(3):319-26.
    View in: PubMed
    Score: 0.042
  57. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging. 2004 May-Jun; 25(5):599-602; discussion 603-4.
    View in: PubMed
    Score: 0.042
  58. Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. J Neurosci Res. 2004 Mar 01; 75(5):698-703.
    View in: PubMed
    Score: 0.041
  59. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res. 2002 Nov 01; 70(3):357-60.
    View in: PubMed
    Score: 0.038
  60. The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol. 2011 Jul; 70(7):578-87.
    View in: PubMed
    Score: 0.017
  61. Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease. J Neurosci Methods. 2010 Jul 15; 190(2):244-7.
    View in: PubMed
    Score: 0.016
  62. Phosphorylated tau: toxic, protective, or none of the above. J Alzheimers Dis. 2008 Aug; 14(4):377-83.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.